PHAXIAM Therapeutics S.A. (PHXM.PA)
EUR 0.31
(-27.91%)
EUR 0.31
(-27.91%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.32 Million EUR | -80.05% |
| 2022 | 6.64 Million EUR | 59.02% |
| 2021 | 4.17 Million EUR | 12.43% |
| 2020 | 3.71 Million EUR | -29.62% |
| 2019 | 5.28 Million EUR | 0.0% |
| 2018 | - EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| 2016 | - EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 546.5 Thousand EUR | 0.0% |
| 2024 Q1 | 546.5 Thousand EUR | -35.78% |
| 2023 Q3 | 197 Thousand EUR | 41.73% |
| 2023 Q1 | 139 Thousand EUR | -97.34% |
| 2023 FY | 1.32 Million EUR | -80.05% |
| 2023 Q4 | 851 Thousand EUR | 331.98% |
| 2023 Q2 | 139 Thousand EUR | 0.0% |
| 2022 Q2 | - EUR | 0.0% |
| 2022 Q4 | 5.22 Million EUR | 1011.49% |
| 2022 Q3 | 470 Thousand EUR | 0.0% |
| 2022 FY | 6.64 Million EUR | 59.02% |
| 2021 Q2 | - EUR | 0.0% |
| 2021 Q4 | - EUR | 0.0% |
| 2021 FY | 4.17 Million EUR | 12.43% |
| 2020 Q4 | - EUR | 0.0% |
| 2020 FY | 3.71 Million EUR | -29.62% |
| 2020 Q2 | - EUR | 0.0% |
| 2019 Q4 | - EUR | 0.0% |
| 2019 FY | 5.28 Million EUR | 0.0% |
| 2018 FY | - EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| 2016 FY | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Nicox S.A. | 257 Thousand EUR | -415.953% |
| European Medical Solutions | 40.56 Million EUR | 96.731% |
| FERMENTALG | 4.05 Million EUR | 67.316% |
| argenx SE | 1.13 Billion EUR | 99.883% |
| BioSenic S.A. | 543 Thousand EUR | -144.199% |
| Celyad Oncology SA | 102 Thousand EUR | -1200.0% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | 36.464% |
| Onward Medical N.V. | 532 Thousand EUR | -149.248% |
| Oxurion NV | 263 Thousand EUR | -404.183% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.975% |